Appears On
Episode Appearances
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Highest paid female pharma CEO in 2025; left post end of 2025; received significant pay bump”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis